- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
New Colombia Resources collaborate with AiP seeking FDA approval for medical cannabis product
17 October 2016 • Author: Niamh Louise Marriott, Digital Content Producer
New Colombia Resources, a US listed Colombian resource company with metallurgical coal and medical marijuana assets, will be applying for an orphan drug designation with their collaboration partners, Advanced Imaging Projects, for regulatory agency approvals of a cannabinoid pharmaceutical product for multiple medical indications with a focus on treatment of a rare paediatric disease.
Once the application is submitted the designation and/or comments are expected within 90 days. The Company expects to file the application in the next 60 days.
Other companies with cannabis drug applications with the FDA include, GW Pharmaceuticals, Zynerba Pharmaceuticals, and INSYS Therapeutics.
These designations confer significant advantages including waiver of application filing fees, expedited approval, government grants, and reduced number of patients in clinical trials.
Dr Stanley Satz, Chairman and CEO of Advanced Imaging Projects stated, “My sense is that by working together with New Colombia Resources, similarly we could obtain this for the cannabinoid under development.”
New Colombia Resources and Advanced Imaging Partners have been in discussions and meetings in the US and Colombia for the past year and are building a team of physicians, biostatisticians, and toxicologists in preparedness of FDA trials and a pre- IND meeting.
With many more states expected to approve medical marijuana in the upcoming elections, including Florida, they feel it is the best time to submit the application which they’ve been working on for the past year.
The joint venture will seek the collaboration of Colombia’s Ministry of Health for the clinical trial to be conducted in Colombia. The Ministry has publicly expressed interest in bringing Cannabis research to Colombia and the Company feels their project is in line with this aspiration. In late August, New Colombia Resources received a letter from the Presidency of Colombia directo the Health Minister requesting his assistance on behalf of the company’s medical marijuana project.
“There would be great personal satisfaction in this project as I lived in Colombia for 5 years while working for the World Health Organization there,” further commented Dr Satz.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics